PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer

Neoplasma

Volumn 61, Issue 4, 2014, Pages 461-467

  Zhang, Y ^a   Liu, M ^a   Yang, H ^b   Wang, J ^a   Liu, H ^a   Li, X ^a,b   Li, J ^a   Xu, J ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SurExam Bio Tech Co Ltd   (China)

Author keywords

Breast cancer; Docetaxel; Epirubicin; NCT; PIK3CA somatic mutation

Indexed keywords

B RAF KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EXON; EXON 20; EXON 9; FEMALE; GENE EXPRESSION ASSAY; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; LARGE CORE NEEDLE BIOPSY; MAJOR CLINICAL STUDY; MRNA EXPRESSION ASSAY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PIK3CA MUTATION; POINT MUTATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904392089     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_057     Document Type: Article

References (30)

1. BERIWAL S, SCHWARTZ GF, KOMARNICKY L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 12: 159-164. http://dx.doi.org/10.1111/j.1075-122X.2006.00225.x
2. ABRIAL SC, Penault-Llorca F, DELVA R, BOUGNOUX P, LEDUC B ET AL. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005; 94: 255-263. http://dx.doi.org/10.1007/s10549-005-9008-8
3. TEWARI M, KRISHNAMURTHY A, SHUKLA HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008; 17: 301-311. http://dx.doi.org/10.1016/j.suronc.2008.03.003
4. HIRANO A, SHIMIZU T, IMAMURA H, WATANABE O, KINOSHITA J ET AL. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. Anticancer Res 2006; 26: 581-584.
5. LI XR, LIU M, ZHANG YJ, WANG JD, ZHENG YQ ET AL. ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med Oncol 2011; 28 Suppl 1: S48-54. http://dx.doi.org/10.1007/s12032-010-9693-y
6. LI XR, WANG JD, ZHANG YJ, KONG QL, MA B ET AL. Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases. Zhonghua Yi Xue Za Zhi 2009; 89: 87-90.
7. HERTEL PB, TU D, EJLERTSEN B, JENSEN MB, BALSLEV E ET AL. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in highrisk breast cancer patients. Breast Cancer Res Treat 2012; 132: 225-234. http://dx.doi.org/10.1007/s10549-011-1896-1
8. EJLERTSEN B, JENSEN MB, NIELSEN KV, BALSLEV E, RASMUSSEN BB ET AL. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010; 28: 984-990. http://dx.doi.org/10.1200/JCO.2009.24.1166
9. YAO L, LIU Y, LI Z, OUYANG T, LI J ET AL. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol 2011; 22: 1326-1331. http://dx.doi.org/10.1093/annonc/mdq612
10. JACOT W, Lopez-Crapez E, THEZENAS S, SENAL R, FINA F ET AL. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res 2011; 13: R133. http://dx.doi.org/10.1186/bcr3079
11. SHAH SP, ROTH A, GOYA R, OLOUMI A, HA G ET AL. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012; 486: 395-399260.
12. Stemke-Hale K, Gonzalez-Angulo AM, LLUCH A, NEVE RM, KUO WL ET AL. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091. http://dx.doi.org/10.1158/0008-5472.CAN-07-6854
13. BACHMAN KE, ARGANI P, SAMUELS Y, SILLIMAN N, PTAK J ET AL. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775. http://dx.doi.org/10.4161/cbt.3.8.994
14. CIZKOVA M, SUSINI A, VACHER S, Cizeron-Clairac G, ANDRIE UC et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2based subgroups. Breast Cancer Research 2012; 14: R28. http://dx.doi.org/10.1186/bcr3113
15. PARK BH, DAVIDSON NE. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell. 2007; 12: 297-299. http://dx.doi.org/10.1016/j.ccr.2007.10.004
16. JENSEN JD, KNOOP A, LAENKHOLM AV, GRAUSLUND M, JENSEN MB ET AL. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012; 23: 2034-2042. http://dx.doi.org/10.1093/annonc/mdr546
17. GOLDHIRSCH A, WOOD WC, COATES AS, GELBER RD, THURLIMANN B ET AL. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747. http://dx.doi.org/10.1093/annonc/mdr304
18. HAYWARD JL, CARBONE PP, HEUSEN JC, KUMAOKA S, SEGALOFF A ET AL. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-298. http://dx.doi.org/10.1038/bjc.1977.42
19. KUERER HM, NEWMAN LA, SMITH TL, AMES FC, HUNT KK ET AL. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
20. LI G, LUO X, HE J, ZHU Z, YU G et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2011; 49: 191-195. http://dx.doi.org/10.1515/CCLM.2011.040
21. FLAGELLA M, BUI S, ZHENG Z, NGUYEN CT, ZHANG A ET AL. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem 2006; 352: 50-60. http://dx.doi.org/10.1016/j.ab.2006.02.013
22. TENG YH, TAN WJ, THIKE AA, CHEOK PY, TSE GM ET AL. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13: R35. http://dx.doi.org/10.1186/bcr2857
23. KALINSKY K, JACKS LM, HEGUY A, PATIL S, DROBNJAK M ET AL. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059. http://dx.doi.org/10.1158/1078-0432.CCR-09-0632
24. JANKU F, WHELER JJ, WESTIN SN, MOULDER SL, NAING A ET AL. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782. http://dx.doi.org/10.1200/JCO.2011.36.1196
25. OWENS MA, HORTEN BC, DA SILVA MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69. http://dx.doi.org/10.3816/CBC.2004.n.011
26. TIEZZI DG, ANDRADE JM, Ribeiro-Silva A, ZOLA FE, MARANA HR ET AL. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally 300 advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36. http://dx.doi.org/10.1186/1471-2407-7-36
27. VON MINCKWITZ G, UNTCH M, BLOHMER JU, COSTA SD, EIDTMANN H ET AL. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804304. http://dx.doi.org/10.1200/JCO.2011.38.8595
28. CURTIS C, SHAH SP, CHIN SF, TURASHVILI G, RUEDA OM ET AL. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
29. BARBARESCHI M, BUTTITTA F, FELICIONI L, COTRUPI S, BARASSI F ET AL. Different prognostic roles of 308 mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13: 6064-6069. http://dx.doi.org/10.1158/1078-0432.CCR-07-0266
30. KATAOKA Y, MUKOHARA T, SHIMADA H, SAIJO N, HIRAI M ET AL. Association Between Gain-Of-Function Mutations In Pik3ca And Resistance To Her2-Targeted Agents In Her2-Amplified Breast Cancer Cell Lines. Ann Oncol 2010; 21: 255-262. http://dx.doi.org/10.1093/annonc/mdp304